AMRI Initiates Phase I Study on ALB109564
More News related to AMRI
- Jefferies & Co Downgrades Albany Molecular Research (AMRI) to Underperform
- Albany Molecular Research (AMRI) Settles Patent Infringement Litigation Involving Allegra(R)
- AMRI Announces Agreement with Teva Pharmaceuticals and Barr Laboratories to Settle Litigation in ALLEGRA(R) and ALLEGRA(R)D-12 U.S. Patent Dispute
- Morning Movers 11/06: Las Vegas Sands (LVS) Sinks On Filing; Whole Foods (WFMI) Higher
- After-Hours Movers 11/05: Cisco (CSCO) Lower On Guidance, Activision Blizzard (ATVI) Up On Results
More News related to Corporate News
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
AMRI (NASDAQ: AMRI) announced the initiation of its Phase I study of ALB109564(a), a novel tubulin inhibitor, which is designed to kill cancer cells by preventing cell mitosis.
The study will be conducted at four clinical trial sites for a period of nine to twelve months and include up to 40 subjects. The drug will be administered intravenously to cancer patients with advanced solid tumors in an ascending dose study to evaluate the compound's safety, tolerability and pharmacokinetic profile.
"We are pleased to begin the process of enrolling patients and commencing Phase I clinical trials of our compound and are hopeful that this first clinical step will ultimately lead to a new weapon in the fight against cancer," said AMRI Chairman, President and CEO Thomas E. D'Ambra. "The initiation of this study demonstrates the company's ability to leverage its full spectrum of scientific capabilities to generate new products with commercial potential and to execute on the R&D portion of our strategic plan to provide value to stakeholders."
Albany Molecular Research, Inc. provides scientific services, technologies and products. [SM]
Related Categories
Corporate NewsStocks Mentioned
-0.17Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
